-- Immutep (IMMP) 週三早上宣布，美國食品藥物管理局 (FDA) 已授予其藥物eftilagimod alfa治療軟組織肉瘤（一種罕見癌症）的孤兒藥資格認定。 受此消息提振，該公司股價在盤前交易中飆升超過58%。 先前，一項評估efti合併放射治療和Keytruda（帕博利珠單抗）治療軟組織肉瘤的II期臨床試驗公佈了相關數據。研究納入38名患者，達到了主要終點，腫瘤透明變性/纖維化的中位數接近52%，超過了預設的35%的目標值，也高於單獨放療時約15%的歷史基準值。腫瘤透明變性/纖維化是指腫瘤的癒合過程。 該公司表示，該結果在多種肉瘤亞型中均有觀察到，並顯示出與efti一致的免疫活化作用，且安全性良好，未導致計畫手術的延誤。
Price: $0.495, Change: $+0.1838, Percent Change: +58.80%
South Korean shares closed at a new high on Monday, with the primary index crossing the 6,600 level amid a rally led by chip stocks and power equipment manufacturers.The Korea Composite Stock Price Index or Kospi rose 139.4 points, or 2.2%, to end at 6,615.03. The Kosdaq also increased by 22.34 points, or 1.9%, to close at 1,226.18.Shares of chipmakers such as Samsung Electronics (KRX:005930) and SK Hynix (KRX:000660) added over 2% and nearly 6% at market close, while those of Kosdaq-listed Fadu (KOSDAQ:440110) jumped over 19%.Gains were also driven by shares of power equipment manufacturers LS Electric (KRX:010120) and Hyosung Heavy Industries (KRX:298040), which added nearly 13% and 11%, respectively.In corporate news, Fadu posted first-quarter net income of 10.2 billion won, rebounding from a net loss of 12.1 billion won a year earlier, according to a Monday filing with the Korea Exchange.The South Korean chipmaker's sales revenue surged 210% year over year to 59.5 billion won from 19.2 billion won.
UCO Bank (NSE:UCOBANK, BOM:532505) net profit rose to 8.01 billion Indian rupees in the fiscal fourth quarter from 6.52 billion rupees a year ago, according to a Saturday filing to the Indian stock exchanges.Earnings per share during the quarter ended March 31 climbed to 0.64 rupees from 0.56 rupees last year.Interest earned by the lender in fiscal Q4, however, slipped to 66.6 billion rupees from 67.4 billion rupees a year earlier.The bank's board also recommended a dividend of 0.44 rupees per share for the financial year 2025-26.
Prudential (SGX:K6S, HKG:2378) bought back 287,211 shares in London on April 24 at an average price of about 11.20 pounds sterling apiece, according to a Monday Hong Kong bourse filing.The insurer intends to cancel the repurchased shares.Following the transaction, the company will have about 2.52 billion shares in issue.